Transaction costs and capabilities as determinants of the R&D boundaries of the firm: a case study of the ten largest pharmaceutical firms in Japan
Transaction costs and capabilities as determinants of the R&D boundaries of the firm: a case study of the ten largest pharmaceutical firms in Japan
复制标题
交易成本和能力作为 R 的决定因素
DOI：
10.1002/mde.1083
复制
发表时间：
2003
影响因子：
2.2
通讯作者：
H. Odagiri
中科院分区：
文献类型：
--
作者：
H. Odagiri
企业的边界是一个重要的问题，不仅关系到生产中的制造或购买决策，而且还关系到研发(R&D)。公司依赖大学获得科学知识，外包一些研发工作，购买专利技术，委托研究，并参与财团。本文以日本10家主要制药公司为例，说明它们与国内外不同的合作伙伴建立了不同类型的研究联盟。讨论了解释研究联盟边界的两种主要理论：交易成本理论和能力理论，并认为观察到的研究联盟模式与能力理论更一致。对这些公司参与的财团和国家项目也进行了讨论。版权所有©2003 John Wiley&Sons，Ltd.
The boundaries of the firm are an important issue in relation not just with the make-or-buy decision in production but also with research and development (R&D). Firms depend on universities to gain scientific knowledge, outsource some of their R&D works, purchase patented technologies, commission research, and participate in consortia. In this paper, we take the case of the 10 major pharmaceutical companies in Japan and show that they employ various types of research alliances with various partners, domestic or foreign. Two major theories to explain the boundaries, the transaction-cost theory and the capability theory, are discussed and we argue that the observed pattern of research alliance is more consistent with the capability theory. Discussion is also made on the consortia and national projects these firms participate. Copyright © 2003 John Wiley & Sons, Ltd.